Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK

Becker, Claudia and Jick, Susan S. and Meier, Christoph R.. (2008) Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. Drug safety, 31 (5). pp. 399-407.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6006076

Downloads: Statistics Overview


Case reports have related the use of HMG-CoA reductase inhibitors ('statins') to Parkinson's disease (PD). Paradoxically, however, statins may have potentially beneficial effects on neurodegenerative diseases due to their anti-inflammatory properties.; To explore the risk of the development of PD in association with untreated hyperlipidaemia and with hyperlipidaemia treated with lipid-lowering drugs in the UK primary care setting.; We conducted a case-control analysis using the UK-based General Practice Research Database (GPRD). Cases were incident PD cases > or =40 years of age between 1994 and 2005. One control was matched to each PD case based on age, sex, general practice and index date. Lipid-lowering drug use was assessed by exposure timing (current vs past use) and by exposure duration (1-9, 10-29 or > or =30 prescriptions) prior to the index date for both cases and controls. Odds ratios (OR) were calculated using conditional logistic regression, adjusted for body mass index, smoking and various cardiovascular, metabolic and psychiatric co-morbidities.; We identified 3637 cases with an incident idiopathic PD diagnosis, and the same number of controls. Compared with patients without hyperlipidaemia, those with untreated hyperlipidaemia did not have an altered relative PD risk (adjusted OR 0.98, 95% CI 0.74, 1.30). The adjusted ORs for current use of > or =30 prescriptions for statins or fibrates compared with non-use of statins or fibrates were 1.06 (95% CI 0.75, 1.51) and 1.25 (95% CI 0.51, 3.06), respectively.; In this observational study, the long-term use of statins or fibrates was not associated with a substantially altered relative risk of developing PD.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Klinische Pharmakologie > Klinische Pharmakologie (Krähenbühl)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Klinische Pharmakologie > Klinische Pharmakologie (Krähenbühl)
05 Faculty of Science > Departement Pharmazeutische Wissenschaften > Pharmazie > Molecular and Systems Toxicology (Odermatt)
UniBasel Contributors:Meier, Christoph R. and Becker, Claudia
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Adis International
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:13 Apr 2021 12:33
Deposited On:11 Oct 2012 15:30

Repository Staff Only: item control page